Phase A — Understand the business
Lens 1 · Company Overview
BWXT is a ~100-year-old specialty manufacturer of nuclear components, fuel, and services. It is not a "nuclear stock" in the uranium-spot sense — it is a precision heavy-manufacturing monopoly wrapped around two end markets that almost no one else is legally or technically allowed to serve. Two reportable segments:
- Government Operations (FY2025 revenue $2,350.1M, 73% of total) — designs and manufactures naval nuclear reactor cores, components and fuel for the U.S. Naval Nuclear Propulsion Program (submarines + aircraft carriers) via the DOE/NNSA; downblends Cold War HEU; runs DOE/NNSA/NASA sites through joint ventures; and develops advanced/space microreactors.
- Commercial Operations (FY2025 revenue $853.1M, 27%) — the only commercial heavy nuclear component manufacturer in North America (steam generators, pressure vessels, reactor components, spent-fuel storage), CANDU fuel/services concentrated in Canada, plus a fast-growing medical radioisotope/radiopharmaceutical business turbo-charged by the May-2025 Kinectrics acquisition.
Contract structure / payment terms — the moat shows up in the contract mix. Government Ops runs primarily on fixed-price-incentive-fee and cost-plus government contracts under FAR/CAS, with award/incentive fees tied to performance scores; Commercial Ops is competitively-bid firm-fixed-price and time-and-materials. Q1 2026 revenue by type: Fixed-Price Incentive Fee $262.9M, Firm-Fixed-Price $379.2M, Cost-Plus $108.0M, Time-and-Materials $111.5M. Revenue is recognized over time on a cost-to-cost percentage-of-completion basis — efficient, but (see Lens 10) it is also the accounting seam where estimate-revision risk lives.
Customers — extreme concentration, but the good kind: in Q1 2026 the U.S. Government was 89% of Government Ops revenue (91% FY2025), and two large utility customers were 61% of Commercial Ops revenue (63% FY2025). The counterparty is the U.S. Navy and a handful of nuclear utilities — sticky, multi-decade, and effectively un-defectable.
Lens 2 · Supply Chain
Map the chain end-to-end with the actual named stakeholders:
Upstream inputs → BWXT. Raw materials are carbon/alloy steels, nickel-based alloys, tubing, forgings, weld wire — "available from numerous sources," purchased per-contract, with single-source suppliers for certain specialty materials that BWXT and the U.S. Government jointly monitor. BWXT itself sits upstream of the rest of the nuclear chain — it processes uranium (Lynchburg VA, Erwin TN), and is the largest domestic supplier of research-reactor fuel elements.
BWXT → end customer.
- Naval / government channel: BWXT reactor cores and components → prime shipbuilders Huntington Ingalls Industries (Newport News) and General Dynamics Electric Boat → U.S. Navy. BWXT is the sole-source core supplier — a single chokepoint the entire submarine industrial base depends on.
- DOE site-management channel: via JVs — e.g. Newport News Nuclear BWXT-Los Alamos (with HII Technical Solutions) at Los Alamos; Lawrence Livermore National Security LLC (with University of California, Bechtel, Amentum).
- Commercial nuclear channel: BWXT heavy components + Kinectrics lifecycle services → nuclear utilities (concentrated in Canada/CANDU and the US fleet undergoing refurbishment/life-extension).
- Medical isotope channel: Isogen (a Framatome–Kinectrics JV) uses CANDU reactors to irradiate targets → isotope processors → radiopharma manufacturers.
Chokepoints / single-source dependencies: BWXT is the chokepoint on the naval side. The vulnerability runs the other way — its own dependence on single-source specialty-material suppliers and on a skilled, security-cleared, partly-unionized workforce (~10,400 employees: 6,700 US, 3,500 Canada). Names or it didn't happen: HII, General Dynamics Electric Boat, Bechtel, Amentum, University of California, Framatome, Cameco, Doosan, AECON — all appear by name in the franchise's orbit.
Lens 3 · Competitive Advantages (moats)
This is the cleanest moat in the energy beat. BWXT's own words: in Government Ops "competition is limited" because of "the technical and regulatory standards… and the barriers to entry," with classified designs requiring U.S. Government security clearances. The moat stack:
- Regulatory/clearance moat — naval reactor work is classified; you cannot enter without clearances, a CAS-compliant accounting system, and a multi-decade qualification history (BWXT has supplied since the 1950s).
- Capital + process moat — clean-room facilities able to assemble railcar-sized nuclear components; "only commercial heavy nuclear component manufacturer in North America." Replicating this is a billion-dollar, multi-year build that no rational competitor underwrites against a single-buyer market.
- Sole-source / switching-cost moat — the Navy has qualified one core supplier. Switching cost is national-security-prohibitive.
- Bargaining power — asymmetric toward customers in pricing (it is a monopsony-ish buyer set: the U.S. Government), but asymmetric in BWXT's favor on continuity — the Navy needs BWXT more than BWXT needs any single award, evidenced by multiyear pricing agreements and the $2.37B of unfunded backlog the Navy keeps loading. Patents exist across reactors/fuel/additive manufacturing/space propulsion but management explicitly says it relies on know-how, not any single patent.
Named competitors (for completeness): Government Ops — Northrop Grumman, Huntington Ingalls, Honeywell, Leidos, Westinghouse, AtkinsRéalis; Commercial Ops — Framatome, Cameco, Doosan Heavy, AECON, Westinghouse. But in the core naval franchise the practical competitor count is zero.
Lens 4 · Segments
All figures (FY) and (Q1):
| Segment / line | FY2023 | FY2024 | FY2025 | FY25 op margin | Trend |
|---|
| Government Ops rev | $2,031.3M | $2,183.0M | $2,350.1M | — | steady +8%/yr |
| — Nuclear Components & Fuel | $1,610.2M | $1,692.2M | $1,796.4M | — | the naval core engine |
| — Uranium Processing & Nuclear Svcs | $276.7M | $287.0M | $406.6M | — | accelerating (enrichment + A.O.T.) |
| — Advanced Reactor Design & Eng | $144.5M | $203.8M | $147.1M | — | lumpy/decelerating (program timing) |
| Gov Ops operating income | $374.7M | $377.9M | $394.9M | 16.8% | stable, high |
| Commercial Ops rev | $466.3M | $524.0M | $853.1M | — | +63% FY25, M&A-led |
| — Nuclear Manufacturing | $231.9M | $288.8M | $429.2M | — | refurb cycle + capacity |
| — Nuclear Services & Engineering | $234.4M | $235.2M | $423.8M | — | Kinectrics step-change |
| Comm Ops operating income | $37.5M | $46.8M | $57.7M | 6.8% | margin lags Gov Ops badly |
| Total revenue | $2,496.3M | $2,703.7M | $3,198.4M | 12.6% consol. | +18.3% FY25 |
Geography (net PP&E, a proxy for footprint): US $870.4M, Canada $702.4M (Kinectrics added ~$240M Canada), other $14M. The business is now meaningfully bi-national, importing FX and Canadian tax-rate (25%) drag.
Read-through: Government Ops is the margin and moat; Commercial Ops is the growth and the risk — its 6.8% margin is less than half Gov Ops', and most of its FY25 growth was bought, not earned (Q1 2026: Kinectrics supplied $105.3M of the $155.3M commercial increase = ~68% acquisition-driven ).
Phase B — Measure performance
Lens 5 · Earnings Result (Q1 2026 — latest print, filed 2026-05-04)
The cleanest "beat-and-raise" in the dossier. GAAP figures ; non-GAAP/consensus .
- Revenue $860.2M, +26.1% YoY (from $682.3M); ~11% organic, the rest Kinectrics/A.O.T.
- Operating income $106.7M (12.4% margin) vs $96.6M; GAAP diluted EPS $0.99 vs $0.82 (+21%); net income to BWXT $91.1M.
- Non-GAAP EPS $1.12 vs $0.92 consensus = +21.7% beat; adjusted EBITDA $148.0M.
- Segments: Gov Ops $577.9M (+4.1%), op income $99.1M (17.2% margin — A.O.T. + enrichment, partly offset by softer advanced-tech); Commercial $283.6M (+121%), op income $24.0M (8.5%, up from 5.0% on mix + Kinectrics).
- Guidance RAISED (the catalyst): FY2026 non-GAAP EPS to $4.60–$4.75 (from $4.55–$4.70), adj EBITDA $650–665M, FCF $315–330M, revenue >$3.75B.
- Balance-sheet flags: cash $512.4M; LT debt $2,017.9M; backlog $8,650.8M vs $7,260.7M at YE2025 (+19% in one quarter); operating cash flow $92.6M (+83% YoY); equity in income of investees $21.6M (+30%); effective tax rate 15.0% (vs 17.7%) on equity-comp excess benefits. Working capital $942.2M.
- Watch item vs own history: receivables fell while contracts-in-progress/unbilled rose (+$51M unbilled to $645.7M) — normal for the FPIF retainage seasonality management flags (Q1/Q3 build, Q2/Q4 collect), but worth tracking.
- Market reaction: stock +0.78% to ~$218 after-hours; +13% YTD by May 5. Muted pop = the beat was largely expected; the backlog is what re-rated the name through the spring.
Also announced with the print: intent to acquire Precision Components Group (PCG) — heavy-walled/heat-transfer components, expands US commercial nuclear capacity, closing H2 2026.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts on disk (transcripts=0), so `` + the filing-embedded quarterly data. Tone trajectory across FY2025→Q1 2026 is unambiguously accelerating-confident: the language shifted from "streamlined talent acquisition / sequential margin improvement" (2023, a labor-constrained defensive tone) to "commercial surge," "beat-and-raise," and emphasis on backlog at $8.65B, +77% YoY by Q1 2026. The recurring phrases now: backlog, naval multiyear awards, microreactor (Pele), Kinectrics, capacity expansion, capital deployment. What they stopped saying: the 2022–23 hand-wringing about a "tough labor market" in Government Ops. Management is leaning into a growth narrative for the first time in years — appropriate given the order book, but it is also what sets up expectation risk (Lens 12/13).
Lens 7 · Comps
Peer set = nuclear-exposed names the market actually baskets BWXT with. Multiples are `` with date or n/a; BWXT has no true peer (no other listed sole-source naval reactor maker), so treat this as a sanity check on the multiple, not a like-for-like.
| Company | Ticker | Mkt cap | Fwd P/E | EV/EBITDA | Div yield | ROE | Note |
|---|
| BWX Technologies | BWXT | ~$18.8B | ~43.9x | ~39–45x | 0.53% | ~28.4% | sole-source naval; monopoly franchise |
| Cameco | CCJ | $45.05B | 57–63x (one src 120x) | n/a | ~0.11% | n/a | uranium miner — even richer |
| Centrus Energy | LEU | $3.77B | ~63x | n/a | none | n/a | enrichment; HALEU optionality |
| Huntington Ingalls | HII | ~$11.7B | 19.5x | n/a | 1.83% | 12.4% | naval prime — the "cheap defense" anchor |
Read-through: BWXT's ~44x forward earnings is expensive in absolute terms and ~2.2x the defense-prime anchor (HII at 19.5x), but cheaper than the uranium/enrichment cohort (Cameco/Centrus 57–120x). The market is pricing BWXT as a nuclear-renaissance growth compounder, not a defense contractor. BWXT's ~28% ROE is genuinely elite — but note it is flattered by a buyback-shrunk equity base ($1.16B avg equity against $2.0B debt), so it reads higher than the underlying business returns.
Lens 8 · Stock-Price Catalysts (5-year >5% movers)
The pattern reveals what this stock actually reacts to: naval contract awards and the nuclear-renaissance narrative, far more than any single quarter. `` throughout.
- 2021–22 derating: −37.2% from the Apr-2021 high through the 2022 inflation shock — rate-driven multiple compression on a long-duration industrial, plus Government Ops labor headwinds.
- 2023 inflection: double-digit organic growth + margin recovery restarts the re-rate. From Feb-2023 to Mar-2026 the stock rose +229%, of which ~139% was P/E-multiple expansion (NOT earnings). ← the single most important sentence for the bear case.
- Jul 2025: ~$2.6B Virginia/Columbia/Ford-class reactor-component awards; Gov Ops backlog to $4.4B.
- Aug–Dec 2025: Project Pele core fabrication begins (Lynchburg); TRISO fuel delivered to Idaho National Lab — first US advanced microreactor, electricity targeted 2028.
- Feb 2026: Q4/FY2025 print + initiates 2026 guidance; Apr 15, 2026 all-time-high close $238.10.
- May 2026: Q1 beat-and-raise + PCG acquisition + an additional ~$1.4B naval propulsion award.
The tape reacts to order flow and narrative, with earnings as confirmation. That cuts both ways (Lens 13).
Phase C — Judge people & books
Lens 9 · Management
CEO Rex D. Geveden — President & CEO since January 2017 (COO 2015–16), age 64; physics degrees (Murray State); previously NASA Associate Administrator overseeing a ~$16B technical portfolio across a 17-year NASA career.
- Track record (quantified): under Geveden, revenue grew from ~$1.6B (2017) to $3.2B (FY2025), with the stock compounding into a top defense/nuclear performer; he steered BWXT through the 2022 labor crunch and executed the pivot into medical isotopes (Kinectrics) and microreactors (Pele). A credible, technically-literate operator for a classified-nuclear business.
- Skin in the game / comp: 2025 total comp $15.7M, +48% YoY (from ~$8.2M) — the raise is large and worth a governance eyebrow, though it tracks the stock's outperformance and is mostly equity. Insider ownership is modest (professional-manager profile, not founder);
insider-transactions.csv absent, so ownership detail is n/a.
- Capital allocation: disciplined-aggressive. FY2025 capex $184.6M (5.8% of revenue) into naval/commercial capacity; ~$440M for Kinectrics + $101M A.O.T. + pending PCG; a steadily-raised dividend ($0.25→$0.27/qtr); opportunistic buybacks ($347.6M remaining authorization); and a shrewd $1.25B 0%-coupon convertible (2030, $262.51 strike) with a capped call to $396.24 — financing growth at a zero cash-coupon. ROE ~28% and ROIC comfortably above cost of capital on his watch.
- Red flags: the comp jump; growth increasingly bought via M&A (integration + goodwill risk); otherwise clean — no related-party deals, no promotional behavior, no strategy whiplash.
- Archetype: seasoned professional manager running a national-asset franchise — exactly the right profile for this stage. CFO Mike T. Fitzgerald; CAO Kevin J. Gorman; new Chief Nuclear Officer Kevin M. McCoy (hired 2025 to accelerate Columbia/Virginia sub cadence).
Lens 10 · Forensic Red Flags
Acting forensically across the three statements; every figure `` unless noted.
- Revenue recognition (the #1 watch): ~96% of revenue is over-time, cost-to-cost percentage-of-completion — inherently estimate-dependent. The filings disclose cumulative catch-up adjustments: Q1 2026 reduced revenue $5.3M / operating income $5.7M; FY2025 increased revenue $5.5M / operating income $4.3M, including a +$29.4M favorable adjustment on a single nuclear-operations contract in Q2 2025. These are disclosed and not enormous relative to a $3.2B base, but they are the lever by which earnings could be smoothed — monitor for recurrence/direction.
- Cash vs earnings: FY2025 net income $329.9M; the JV "Equity in Income of Investees" of $74.9M (18% of operating income) is non-cash until distributed — quality-of-earnings caveat, though investee dividends have historically followed. Q1 operating cash flow $92.6M comfortably exceeded net income, so no near-term divergence.
- Receivables/inventory vs revenue: unbilled receivables rose to $645.7M (Q1) and retainages to $77.5M on FPIF seasonality — explainable, not alarming, but unbilled growing faster than revenue is the classic POC tell to watch.
- Goodwill/intangibles: $496.3M goodwill + $321.4M intangibles (Q1) post-Kinectrics/A.O.T.; Kinectrics purchase accounting is still preliminary ("subject to change… may be material") and it was excluded from the FY2025 ICFR assessment (16.3% of assets, 7.1% of revenue). Integration + an unfinished PPA is a legitimate near-term risk surface.
- SBC / non-GAAP: SBC doubled YoY to $10.2M in Q1; the $0.13 GAAP-to-non-GAAP EPS gap ($0.99 vs $1.12) is real and recurring — non-GAAP flatters by ~13%. Hold management to GAAP.
- Leverage: $2.02B gross debt; net debt ~$1.51B; net leverage ~2.3x / gross ~3.1x guided FY26 adj EBITDA — inside the 4.0x covenant, investment-grade-track, with an undrawn $1.25B revolver. Healthy.
Regulatory findings (required sub-section).
- SEC Litigation Releases: none naming BWX Technologies (EDGAR EFTS, 2021-06-20 → 2026-06-20).
- SEC AAERs: none.
- 10-K Item 3 (Legal Proceedings) / Q1 Note 5: management states "There were no material contingencies" in Q1 2026; the 10-K discloses only ordinary-course matters.
- Non-SEC web screen (
"BWX Technologies" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty)): no material enforcement actions surfaced. As a cleared DOE/Navy contractor BWXT carries the standard suspension/debarment exposure if ever indicted, but nothing is pending.
- Auditor: Deloitte & Touche LLP — unqualified opinion on FY2025 financials and on ICFR (Kinectrics carve-out noted).
- Verdict: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 / 10-Q Note 5 as of 2026-06-21.
Phase D — Project & stress-test
Lens 11 · Forward Projection (EPS, next three fiscal years)
Built bottom-up from FY2025 actual ($3.58 GAAP / ~$4.20 non-GAAP est.) and the company's raised FY2026 guidance. Output ``; inputs labeled.
Anchor (FY2026, base = guidance midpoint):
- Revenue >$3.75B (+~17% on FY25's $3.20B; ~half organic, ~half Kinectrics/A.O.T./PCG annualization)
- Adj EBITDA $650–665M (mid $657.5M); non-GAAP EPS $4.60–$4.75 (mid $4.675); FCF $315–330M.
Three-year base / bull / bear (non-GAAP EPS):
| Scenario | FY2026 | FY2027 | FY2028 | Logic |
|---|
| Base | $4.68 (guide) | ~$5.28 | ~$5.97 | ~13% EPS CAGR: rev +~10%/yr off $8.65B backlog (60% recognized by end-2027), modest Gov-Ops operating leverage + Kinectrics margin lift, ~1% buyback accretion |
| Bull | $4.75 | ~$5.70 | ~$6.73 | ~20% CAGR: Pele/microreactor monetizes, naval multiyear pricing steps up, Commercial margin → low-teens, PCG accretive |
| Bear | $4.60 | ~$4.85 | ~$5.15 | ~5% CAGR: Kinectrics integration drags margin, advanced-reactor revenue stays lumpy, capex/working-capital crimps FCF |
The valuation math that matters: at $205.40, the base case implies ~44x FY26 → 39x FY27 → ~34x FY28 non-GAAP EPS. Even three years out and on the bull path ($6.73), you are paying ~31x. The business almost certainly grows into the bull EPS; the question is whether the multiple survives the journey.
No forecast.ts create run (watchlist/breadth mode — Brier logging is reserved for a committed base call in /thesis). The natural tracked forecast to log on promotion: "BWXT FY2028 non-GAAP EPS ≥ $5.90, p≈0.55."
Lens 12 · Bull vs Bear
Bull case. BWXT owns the single most defensible position in US energy/defense manufacturing: the sole-source naval reactor franchise, re-rating on a generational submarine build-out (Columbia + Virginia + AUKUS demand), a record $8.65B backlog (+77% YoY) with $2.37B unfunded upside and $1.4B of unexercised options ($900M due ~2030, $500M ~2035) not even in backlog. On top of the defense annuity sit two genuine call options the market is starting to pay for: Project Pele (first US microreactor, the on-ramp to a defense/space/data-center microreactor product line) and medical isotopes (Kinectrics/Isogen — a high-margin, secularly-growing radiopharma franchise). Capital allocation is excellent (0%-coupon convert, disciplined M&A, ~28% ROE). This is a compounder with a moat the width of a national-security mandate.
Bear case (2–3 permanent-impairment risks + what's priced in).
- Multiple, not business. ~139% of the 2023→2026 move was P/E expansion, not earnings. At ~44x forward on an industrial, a rate-up cycle or a single nuclear-renaissance sentiment wobble can take 30–40% off the price with the business completely intact. DCF models put intrinsic value at $95–$121 vs ~$205 ("70–142% overvalued").
- Single-customer dependence. 89% of Government Ops is the U.S. Government. A debt-ceiling fight, prolonged continuing resolution, government shutdown, or Navy shipbuilding-budget cut (all explicitly flagged in the 10-K risk factors) would hit the annuity directly.
- M&A-bought growth + integration/accounting fragility. A large share of FY25/Q1 growth was acquired (Kinectrics ~68% of the Q1 commercial increase); the Kinectrics PPA is still open and may move materially; cost-to-cost POC accounting plus a 2027/28 debt-refi cluster (the 4.125% 2028 + 2029 notes) make reported earnings more fragile than a 44x multiple assumes.
Pre-mortem (18 months out, thesis broke): rates backed up / nuclear-renaissance euphoria cooled, the multiple compressed from 44x toward HII-like 20–25x, and a Kinectrics integration miss or a continuing-resolution-driven Government-Ops air-pocket gave the de-rate a fundamental excuse. EPS still grew ~10%; the stock fell 35% anyway. The thesis didn't break — the price did.
Are multiples too high? Yes, in absolute terms (44x fwd) — but rational relative to the nuclear cohort and the moat. The honest answer: the quality is real and the price has borrowed several years of it forward.
Contrarian view (what the market refuses to see): consensus treats BWXT as a one-way nuclear-renaissance call. The market is under-pricing the government-budget fragility of an 89%-U.S.-Government revenue base and over-pricing the near-term monetization of Pele/microreactors (electricity not until 2028; commercial scale years beyond). The franchise is a buy; the entry price is the entire debate.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case. What structurally breaks the way BWXT makes money?
- Revenue concentration: 89% U.S. Government + two utilities at 61% of Commercial. The bull calls this "sticky"; the short calls it "one budget line away from an air pocket." A Navy procurement reprioritization, a multi-month CR, or a shutdown converts the annuity into a cancellation/deferral risk the 10-K itself enumerates.
- Moat weaker than bulls think? Not really on naval — but the microreactor/SMR optionality bulls are capitalizing is speculative: "expectations… running ahead of regulatory and execution realities." If Pele slips past 2028 or the commercial microreactor TAM stays a PowerPoint, a chunk of the multiple is air.
- Most dangerous competitor bulls underestimate: not a rival manufacturer (there is none) — it's the U.S. Government as monopsony pricing-setter. On FPIF/cost-plus work, the customer controls the fee. Margin expansion in Government Ops is granted, not won.
- Worst capital-allocation / accounting flags: aggressive M&A into an open Kinectrics PPA; cost-to-cost POC with recurring (if modest) catch-up adjustments and an exclusion of Kinectrics from ICFR; a CEO comp jump to $15.7M. None individually damning; collectively they raise the earnings-quality bar that a 44x multiple ignores.
- Assumptions that must hold for $205: (a) the ~44x multiple persists; (b) naval budgets keep growing through any fiscal fight; (c) Kinectrics integrates without margin drag; (d) microreactors monetize this decade. Break any one and the stock de-rates.
- −20–30% growth-disappointment scenario: if FY27/28 EPS lands bear (~$4.85–$5.15) instead of base, and the multiple normalizes toward 25–30x, the stock is $120–$155 — i.e. −25% to −40% from $205, squarely inside the DCF intrinsic range.
- Single scenario that permanently impairs: a structural cut to the U.S. submarine/carrier build rate (budget crisis or strategic pivot). Plausibility: low but non-zero, and it is the only thing that genuinely impairs the franchise rather than the multiple.
Lens 14 · Management Questions (ordered by information value)
- At ~44x forward earnings, what specifically must the market keep believing for the stock to compound from here — and where do you think consensus is wrong?
- How much of FY2026's >$3.75B revenue is organic vs. annualized M&A (Kinectrics/A.O.T./PCG), and what is the underlying organic growth rate ex-acquisitions?
- Kinectrics purchase accounting is still preliminary — what is the realistic range of final goodwill/intangibles, and when does it close?
- Walk us through the 2027/2028 debt-refi cluster (4.125% 2028 + 2029 notes) — refinancing plan, rate assumptions, and the EPS sensitivity.
- What gets Commercial Operations margin from 6.8% to Government-Ops-like mid-teens, and on what timeline?
- Quantify Project Pele's path to revenue: when does the microreactor line move from cost-plus development to a scalable commercial product, and what's the addressable market you actually underwrite?
- How exposed is the FY2026 plan to a prolonged continuing resolution or government shutdown — which programs are funded vs. at risk?
- What is the cash-conversion bridge from ~$4.68 non-GAAP EPS to $315–330M FCF, given working-capital and growth-capex intensity?
- The $1.4B of unexercised options excluded from backlog ($900M ~2030, $500M ~2035) — what's the probability and timing you'd assign to those awards?
- How do you think about the buyback at this valuation vs. retaining dry powder for the next acquisition?
- What share of Government Ops operating income is award/incentive fee that the customer can withhold, and how has the realization rate trended?
- Equity-method JV income is ~18% of operating income and non-cash until distributed — what is the cash-distribution outlook from the DOE-site JVs?
- AUKUS and allied submarine demand — what's the realistic incremental revenue opportunity and the capacity/clearance constraints to capturing it?
- Where are you most supply-constrained (specialty materials, cleared labor, facility throughput), and what is the capex runway to debottleneck?
- If you had to name the one thing that would make you wrong over the next three years, what is it?